{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment","groups":[{"description":"INCAGN01949 7mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG000","title":"PART 1 Dose 1 (7 mg)"},{"description":"INCAGN01949 20mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG001","title":"PART 1 Dose 2 (20 mg)"},{"description":"INCAGN01949 70mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG002","title":"PART 1 Dose 3 (70 mg)"},{"description":"INCAGN01949 200mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG003","title":"PART 1 Dose 4 (200 mg)"},{"description":"INCAGN01949 350mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG004","title":"PART 1 Dose 5 (350 mg)"},{"description":"INCAGN01949 700mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG005","title":"PART 1 Dose 6 (700 mg)"},{"description":"INCAGN01949 1400mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG006","title":"PART 1 Dose 7 (1400 mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Full Analysis Set population include all subjects enrolled in the study who received at least 1 dose of INCAGN01949.","reportingStatus":"POSTED","timeFrame":"From screening through 60 days after end of treatment, up to 11 months","title":"Number of Participants With Treatment-related Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}